Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice

Area of Science:

• Nephrology and Diabetes Research
• Molecular and Cellular Biology
• Fibrosis Mechanisms

Background:

• Diabetic nephropathy (DN) involves kidney damage, mesangial proliferation, and extracellular matrix (ECM) production.
• Activated protein C (APC) ameliorates DN via protease-activated receptor-1 (PAR-1), suggesting a protective role.
• However, PAR-1 activation in certain cells drives fibrosis, creating a paradox in DN pathogenesis.

Purpose of the Study:

• To investigate the net effect of PAR-1 on the progression of diabetic nephropathy.
• To determine if PAR-1 potentiates or protects against diabetes-induced kidney injury.
• To explore PAR-1 as a potential therapeutic target for DN.

Main Methods:

• Studied streptozotocin-induced diabetic nephropathy in wild-type and PAR-1 deficient mice.
• Assessed kidney damage markers: proteinuria, plasma cystatin C, mesangial area expansion, and tubular atrophy.
• Investigated in vitro profibrotic responses of mesangial and tubular epithelial cells with PAR-1 stimulation/inhibition.

Main Results:

• PAR-1 deficient mice exhibited significantly reduced kidney damage compared to wild-type mice, despite similar glucose levels.
• In vitro, PAR-1 signaling increased mesangial cell proliferation and expression of fibronectin and collagen IV.
• PAR-1 deficiency in vivo correlated with reduced mesangial proliferation and fibronectin deposition.

Conclusions:

• Protease-activated receptor-1 (PAR-1) plays a significant role in promoting kidney damage during diabetic nephropathy.
• PAR-1 signaling drives key fibrotic processes, including mesangial cell proliferation and ECM production.
• Targeting PAR-1 presents a promising therapeutic strategy for managing diabetic nephropathy.